Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
ASCO Guidelines
100%
Chemotherapy
50%
Deficient Mismatch Repair (dMMR)
37%
Liver
25%
Microsatellite Stable
25%
Wild-type KRAS
25%
Clinical Practice
12%
Tumor
12%
Selective Internal Radiation Therapy
12%
Expert Panel
12%
Previously Treated
12%
Cancer Guidelines
12%
Randomized Controlled Trial
12%
Liver Metastasis
12%
Left-handed
12%
Inclusion Criteria
12%
Guideline Implementation
12%
Managerial Decision Making
12%
Pembrolizumab
12%
Patient Selection
12%
Shared Decision Making
12%
Systemic Therapy
12%
Guideline Recommendations
12%
Anti-vascular Endothelial Growth Factor Therapy
12%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
12%
Resection
12%
Right-sided
12%
First-line Regimen
12%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
12%
Line of Therapy
12%
BRAF V600E mutant
12%
Treatment-naïve
12%
Gastrointestinal Cancer
12%
Chemotherapy Alone
12%
Surgery Alone
12%
Cetuximab
12%
Preoperative Chemotherapy
12%
Microsatellite Instability-high (MSI-H)
12%
Initially Unresectable
12%
Systemic Chemotherapy
12%
Cytoreductive Surgery
12%
Previously Untreated
12%
Curative Resection
12%
Stereotactic Body Radiation Therapy
12%
Multidisciplinary Team Management
12%
Anti-epidermal Growth Factor Receptor Therapy
12%
Asco
12%
Oligometastases
12%
Triplet Therapy
12%
Encorafenib
12%
Colorectal Peritoneal Metastases
12%
Bilobar Metastases
12%
Medicine and Dentistry
Metastatic Colorectal Cancer
100%
DNA Mismatch Repair
37%
Systematic Review
37%
Neoplasm
12%
Systemic Therapy
12%
Liver Metastasis
12%
Metastatic Carcinoma
12%
Shared Decision Making
12%
Vasculotropin
12%
Gastrointestinal Cancer
12%
Vasculotropin Antibody
12%
Cytoreductive Surgery
12%
Peritoneum Metastasis
12%
Anti-Epidermal Growth Factor Receptor
12%
Stereotactic Body Radiation Therapy
12%
Selective Internal Radiation Therapy
12%
Hyperthermic Intraperitoneal Chemotherapy
12%
Randomized Controlled Trial
12%
Encorafenib
12%
Pembrolizumab
12%
Microsatellite Instability
12%
Cetuximab
12%